Cetuximab, paclitaxel combo active in urothelial cancer
The monoclonal antibody against epidermal growth factor receptor, cetuximab, augments the antitumor activity of paclitaxel in patients with previously treated urothelial cancer, according to a study published online Aug. 27 in the Journal of Clinical Oncology.
(HealthDay)—The monoclonal antibody against epidermal growth factor receptor (EGFR), cetuximab, augments the antitumor activity of paclitaxel in patients with previously treated urothelial cancer, according to a study published online Aug. 27 in the Journal of Clinical Oncology.
Yu-Ning Wong, M.D., of the Fox Chase Cancer Center in Philadelphia, and colleagues conducted a phase II, randomized, noncomparative study involving 39 patients with metastatic urothelial cancer to determine the benefits of salvage chemotherapy with cetuximab with or without paclitaxel.
In the single-agent cetuximab treatment arm, the researchers found that nine of 11 patients had progressed by eight weeks, and the arm was closed. For the 28 patients enrolled in the cetuximab plus paclitaxel arm, 12 experienced progression-free survival (PFS) longer than 16 weeks. The overall response rate was 25 percent, including three complete responses and four partial responses. The median PFS and overall survival were 16.4 and 42 weeks, respectively. Grade 3 and 4 treatment-related adverse events included rash in six patients, fatigue in five patients, and low magnesium in three cases.
"In conclusion, although cetuximab is inactive as a single agent in advanced urothelial cancer, it may augment the antitumor activity of paclitaxel when given in combination," the authors write. "The combination of paclitaxel and cetuximab should be compared with single-agent paclitaxel in a randomized controlled trial to establish the role of EGFR inhibition by monoclonal antibodies in advanced urothelial cancers."
Several authors disclosed financial ties to Bristol-Myers Squibb, which funded the study and manufactures cetuximab.
More information: Abstract
Full Text (subscription or payment may be required)
Journal reference:
Journal of Clinical Oncology
Copyright © 2012 HealthDay. All rights reserved.
-
Colorectal cancer patients with gene mutation show better response to cancer agent
Oct 26, 2010 |
not rated yet |
0
-
Study finds that lung cancer patients respond to erlotinib following cetuximab therapy
Aug 02, 2009 |
not rated yet |
0
-
High EGFR expression a predictor for improved survival with cetuximab plus chemotherapy
Jul 05, 2011 |
not rated yet |
0
-
New recommendations issued for use of cetuximab in colon cancer therapy
Jul 16, 2010 |
not rated yet |
0
-
Study combines lapatinib with cetuximab to overcome resistance in EGFR-driven tumors
May 16, 2012 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
How can there be villous adenoma in colon, if there are no villi there
1 hour ago
-
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013
-
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013
-
If you became brain-dead, would you want them to pull the plug?
May 17, 2013
-
MRI bill question
May 15, 2013
-
Ratio of Hydrogen of Oxygen in Dessicated Animal Protein
May 13, 2013
- More from Physics Forums - Medical Sciences
More news stories
Cancer survivors need more support to stop smoking and drinking
Cancer survivors are no more likely to stop smoking, cut down on alcohol, or exercise more often than the general population, according to new research published in the British Journal of Cancer today (Wednesday)
Cancer
50 minutes ago |
not rated yet |
0
Beta-blockers may boost chemo effect in childhood cancer
Beta-blockers, normally used for high blood pressure, could enhance the effectiveness of chemotherapies in treating neuroblastoma, a type of children's cancer, according to a new study published in the British Jo ...
Cancer
1 hour ago |
not rated yet |
0
Japan hospital tests powerful breast cancer therapy
A Japanese cancer specialist said Wednesday she has started the world's first clinical trial of a powerful, non-surgical, short-term radiation therapy for breast cancer.
Cancer
1 hour ago |
not rated yet |
0
Small cancer risk following CT scans in childhood and adolescence confirmed
The gap between life expectancy in patients with a mental illness and the general population has widened since 1985 and efforts to reduce this gap should focus on improving physical health, suggest researchers in a paper ...
Cancer
14 hours ago |
not rated yet |
0
Changing cancer's environment to halt its spread
By studying the roles two proteins, thrombospondin-1 and prosaposin, play in discouraging cancer metastasis, a trans-Atlantic research team has identified a five-amino acid fragment of prosaposin that significantly reduces ...
Cancer
15 hours ago |
5 / 5 (1) |
0
A molecular explanation for age-related fertility decline in women
(Medical Xpress)—Scientists supported by the National Institutes of Health have a new theory as to why a woman's fertility declines after her mid-30s. They also suggest an approach that might help slow ...
Medical researchers discover new ways to target, develop and design drugs to prevent and treat viral infection
Researchers at the University of Alberta have discovered a new drug target, developed a new drug and identified a new way to design drugs—all of which could be a winning combination in the battle against viruses.
Alcohol sales fall due to ban on multi-buy promotions
(Medical Xpress)—A report published today shows a 2.6% decrease in the amount of alcohol sold per adult in Scotland in the year following the introduction of the Alcohol etc. (Scotland) Act in October 2011.
Ethicists' behavior not more moral, study finds
(Medical Xpress)—Do ethicists engage in better moral behavior than other professors? The answer is no. Nor are they more likely than nonethicists to act according to values they espouse, according to researchers from the ...
Succesful results in developing oral vaccine against diarrhea
The University of Gothenburg Vaccine Research Institute (GUVAX) announces successful results in a placebo controlled phase I study of an oral, inactivated Escherichia coli diarrhea vaccine.
American, Nepalese kids a world apart on social duties
(Medical Xpress)—Preschoolers universally recognize that one's choices are not always free – that our decisions may be constrained by social obligations to be nice to others or follow rules set by parents ...
